CVS Health Co. (NYSE:CVS) Expected to Announce Earnings of $2.15 Per Share

Wall Street analysts forecast that CVS Health Co. (NYSE:CVSGet Rating) will report earnings per share (EPS) of $2.15 for the current fiscal quarter, according to Zacks. Six analysts have made estimates for CVS Health’s earnings, with estimates ranging from $1.98 to $2.27. CVS Health posted earnings per share of $2.04 in the same quarter last year, which indicates a positive year-over-year growth rate of 5.4%. The business is expected to report its next earnings results before the market opens on Monday, January 1st.

On average, analysts expect that CVS Health will report full year earnings of $8.24 per share for the current fiscal year, with EPS estimates ranging from $8.13 to $8.28. For the next financial year, analysts expect that the company will report earnings of $8.91 per share, with EPS estimates ranging from $8.73 to $8.99. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for CVS Health.

CVS Health (NYSE:CVSGet Rating) last posted its quarterly earnings data on Wednesday, February 9th. The pharmacy operator reported $1.98 EPS for the quarter, topping the consensus estimate of $1.94 by $0.04. The firm had revenue of $76.60 billion during the quarter, compared to analyst estimates of $76.01 billion. CVS Health had a net margin of 2.71% and a return on equity of 15.15%. During the same quarter in the previous year, the business posted $1.30 EPS.

Several analysts have recently commented on the stock. Mizuho upped their price objective on shares of CVS Health from $110.00 to $115.00 and gave the company a “buy” rating in a report on Monday, December 20th. BMO Capital Markets increased their price target on shares of CVS Health from $108.00 to $120.00 in a report on Thursday, February 10th. Raymond James downgraded shares of CVS Health from a “strong-buy” rating to an “outperform” rating and increased their price target for the stock from $115.00 to $120.00 in a report on Friday, February 11th. Sanford C. Bernstein increased their price target on shares of CVS Health from $111.00 to $116.00 in a report on Tuesday, January 11th. Finally, Deutsche Bank Aktiengesellschaft cut shares of CVS Health from a “buy” rating to a “hold” rating and set a $110.00 price objective for the company. in a research report on Tuesday, March 29th. Four research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $113.09.

In other CVS Health news, EVP Troyen A. Brennan sold 47,937 shares of the stock in a transaction dated Thursday, February 3rd. The shares were sold at an average price of $110.00, for a total transaction of $5,273,070.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig acquired 1,000 shares of the stock in a transaction dated Thursday, February 10th. The stock was acquired at an average cost of $105.90 per share, with a total value of $105,900.00. The disclosure for this purchase can be found here. Insiders sold 226,147 shares of company stock valued at $23,949,067 in the last three months. 0.69% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of CVS. West Bancorporation Inc. acquired a new stake in CVS Health in the fourth quarter valued at approximately $25,000. Bell Investment Advisors Inc acquired a new position in shares of CVS Health during the 3rd quarter worth $26,000. Claremont Financial Group Inc. acquired a new position in shares of CVS Health during the 4th quarter worth $26,000. Stuart Chaussee & Associates Inc. raised its stake in CVS Health by 123.0% in the 1st quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 171 shares during the last quarter. Finally, Capital Advisors Ltd. LLC increased its stake in shares of CVS Health by 125.7% during the 4th quarter. Capital Advisors Ltd. LLC now owns 316 shares of the pharmacy operator’s stock valued at $33,000 after acquiring an additional 176 shares during the last quarter. 76.18% of the stock is owned by institutional investors and hedge funds.

CVS stock opened at $103.68 on Wednesday. The firm’s fifty day simple moving average is $104.39 and its 200-day simple moving average is $98.90. The company has a market capitalization of $136.15 billion, a P/E ratio of 17.40, a price-to-earnings-growth ratio of 1.55 and a beta of 0.80. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.88 and a quick ratio of 0.62. CVS Health has a 12 month low of $74.64 and a 12 month high of $111.25.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 2nd. Investors of record on Friday, April 22nd will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.12%. The ex-dividend date is Thursday, April 21st. CVS Health’s dividend payout ratio is currently 36.91%.

CVS Health Company Profile (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Featured Stories

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with's FREE daily email newsletter.